INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN CHEMISTRY AND PHARMACEUTICAL SCIENCES
(p-ISSN: 2348-5213: e-ISSN: 2348-5221)
www.ijcrcps.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijcrcps Coden: IJCROO(USA) Volume 13, Issue 3- 2026

Review Article

DOI: http://dx.doi.org/10.22192/ijcrcps.2026.13.03.003

Blood, Immunity and Longevity: The Untapped Potential of Hematological Research: A Narrative Review

***Emmanuel Ifeanyi Obeagu[1,2]**
[1]Division of Haematology, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.
[2]The Division of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
*Corresponding Author: Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, emmanuelobeagu@yahoo.com,
ORCID: 0000-0002-4538-0161

Abstract

The interplay between blood, immunity, and aging is a critical yet underexplored area in the quest for understanding human longevity. Blood cells, including red blood cells (RBCs), white blood cells (WBCs), and platelets, play pivotal roles in immune function, tissue homeostasis, and overall health. As aging leads to changes in blood composition, the body experiences diminished immune responses, increased inflammation, and reduced tissue regeneration, all of which contribute to age-related diseases. This review investigates how hematological processes influence immunity and aging, focusing on how changes in blood cells affect the body's ability to defend against infections, repair tissues, and maintain resilience against chronic diseases. Emerging evidence suggests that optimizing blood cell function could provide novel therapeutic avenues to enhance healthspan and delay aging-associated decline. The review highlights current research on the molecular mechanisms underlying blood cell aging, the decline in hematopoiesis, and the resulting implications for immune responses. It also explores strategies aimed at rejuvenating blood cells, such as stem cell therapies, gene editing, and immune-modulating drugs, which have the potential to improve immune function, reduce chronic inflammation, and mitigate the effects of age-related diseases like cardiovascular conditions, neurodegeneration, and cancer.

Keywords: *Hematology, Immunity, Longevity, Blood Cells, Aging*

Introduction

Aging is a multifactorial process that affects all systems of the body, and the hematological system is no exception. Blood, which plays a vital role in maintaining homeostasis, is intricately linked to immune function, tissue repair, and the body's overall ability to withstand the wear and tear of age. As individuals age, changes in blood cell production, functionality, and composition contribute significantly to the decline of immune responses and the onset of age-related diseases. However, despite its importance, the role of blood cells and hematological processes in aging remains an underexplored area of research, with vast potential for discovering new interventions aimed at extending healthspan and mitigating the effects of aging [1-2].Blood is composed of a variety of cellular components—red blood cells (RBCs), white blood cells (WBCs), platelets, and plasma—all of which serve unique functions critical to immunity and overall health. RBCs are primarily responsible for oxygen transport, while WBCs form the cornerstone of the immune system, defending the body against infections and regulating inflammatory responses. Platelets, though mainly known for their role in coagulation, also play an integral part in immune modulation and tissue repair. Collectively, these cells contribute to maintaining a robust defense system that is essential for longevity [2].

As we age, however, blood cells undergo several changes that contribute to the aging process itself. For instance, the quantity and functionality of immune cells—especially T-cells, B-cells, and macrophages—decline, making older adults more susceptible to infections, autoimmune diseases, and cancer. Furthermore, chronic low-grade inflammation, often referred to as "inflammaging," becomes more pronounced as blood cells, particularly platelets and monocytes, become increasingly less efficient at regulating inflammatory responses. This inflammation accelerates tissue damage and is a key driver of aging-related degenerative diseases such as cardiovascular disease, neurodegeneration, and frailty [3].Recent research has shown that the integrity of blood cells—specifically their ability to perform their respective functions efficiently—has a direct impact on the aging process and the development of age-related diseases. For example, RBCs, which are crucial for oxygen delivery, gradually lose efficiency with age, impairing oxygenation at the cellular level and contributing to muscle weakness, cognitive decline, and reduced overall vitality. Meanwhile, age-related changes in WBCs undermine immune surveillance, making older individuals more vulnerable to infections and reducing the effectiveness of vaccinations [4-5].

The decline in blood cell function with aging is further compounded by changes in hematopoiesis—the process by which new blood cells are produced. Hematopoietic stem cells (HSCs), which give rise to all blood cell types, become less efficient as individuals age, leading to reduced production of new blood cells and decreased regenerative capacity. This depletion in hematopoietic stem cell function not only affects immune responses but also compromises the body's ability to repair tissues, which accelerates the onset of age-related conditions and diminishes overall healthspan [6-7].

Aim

The aim of this review is to explore the emerging therapeutic strategies that target hematopoiesis and immune modulation to improve immune function, combat age-related diseases, and enhance longevity

Review Methods

This review article was conducted through a systematic examination of current literature, focusing on emerging therapeutic strategies related to hematopoiesis and immune modulation in the context of aging and longevity. The process began by identifying relevant articles and research publications from peer-reviewed journals, conference proceedings, and academic databases,

including PubMed, Google Scholar, and Scopus. The search criteria were designed to capture a broad range of studies published in the last decade (2010-2025) to ensure the inclusion of the most up-to-date findings. The keywords used during the search included "hematopoiesis," "immune modulation," "aging," "longevity," "immune system rejuvenation," "stem cell therapies," "inflammaging," and "senolytics." The review process followed a structured approach, starting with a preliminary screening of titles and abstracts to identify studies most relevant to the research question. Only studies that explored therapeutic interventions aimed at improving blood cell production, immune function, or addressing age-related immune dysfunction were included. Additionally, articles that discussed the molecular mechanisms of aging, immune senescence, and inflammation were considered for inclusion. Studies that were not peer-reviewed, not written in English, or lacked sufficient methodological rigor were excluded to maintain the quality and relevance of the review.

After identifying the eligible studies, a more detailed analysis was conducted. Each study was assessed for its methodology, including the type of interventions tested (e.g., stem cell therapies, immune reprogramming, gene editing, senolytics), the sample population (e.g., aging humans, animal models, cell cultures), and the primary outcomes measured (e.g., immune function, hematopoiesis, inflammation reduction). A narrative synthesis approach was employed to categorize the findings into thematic areas, which included rejuvenating hematopoiesis, immune system reprogramming, inflammatory modulation, and genetic interventions. The synthesis was designed to provide a comprehensive overview of how these emerging therapeutic strategies interact with the aging process, their potential benefits, and the challenges faced in translating these interventions from research to clinical application. Furthermore, the review also incorporated a discussion of clinical trials and ongoing studies, focusing on the therapeutic potential of various interventions and their implications for aging-related diseases. Emphasis was placed on understanding the therapeutic mechanisms, the safety and efficacy of treatments, and the translational challenges associated with each approach. The narrative synthesis was complemented by a critical examination of the limitations of current studies, including sample sizes, the generalizability of results, and the need for further research to refine and validate these therapies.

Blood Cells and Immune System Function

Blood plays a crucial role in maintaining immune system function by providing the cellular components necessary for detecting, defending, and responding to a wide variety of pathogens, toxins, and foreign agents. These cellular components—primarily white blood cells (WBCs), red blood cells (RBCs), and platelets—work synergistically to uphold homeostasis, regulate inflammation, and protect the body against infections and diseases. The immune system, driven largely by these blood cells, orchestrates a highly coordinated response to threats, relying on the complex interplay between innate and adaptive immune cells [8-9].Red Blood Cells (RBCs), although primarily known for their role in oxygen transport, play a lesser-known role in immune function. Recent studies have revealed that RBCs can interact with immune cells, modulating immune responses through their interaction with endothelial cells, platelets, and even direct signaling to immune receptors. Furthermore, they are involved in regulating the levels of carbon dioxide, which can influence inflammatory processes. As RBCs age, their ability to engage with the immune system diminishes, potentially contributing to impaired immune responses seen in older adults [10].

White Blood Cells (WBCs) are the cornerstone of immune defense and are classified into several subtypes, each with specialized functions. These include neutrophils, lymphocytes (T-cells, B-cells, and natural killer cells), monocytes, eosinophils, and basophils. Neutrophils and monocytes are part of the innate immune system,

which provides an immediate, nonspecific response to infections. Neutrophils are the first responders to microbial invasion, while monocytes differentiate into macrophages, which are critical for phagocytosis and the activation of adaptive immunity. In contrast, adaptive immunity, mediated by T-cells and B-cells, is highly specific, capable of recognizing and responding to specific pathogens through memory mechanisms [11].As individuals age, however, there are significant changes in the function and number of WBCs. The thymus, where T-cells mature, shrinks with age, leading to a reduction in the production of naïve T-cells. Consequently, older adults experience diminished adaptive immune responses, making them more susceptible to infections, autoimmune diseases, and cancers. Similarly, B-cells undergo a decline in their ability to produce high-affinity antibodies, compromising the body's ability to fight off infections and respond effectively to vaccinations. The reduced capacity of immune cells to recognize and eliminate pathogens or aberrant cells is a hallmark of immune senescence, a key factor in the aging process [12].

Platelets, often associated with blood clotting, also have vital immune functions. They are involved in the regulation of inflammation, wound healing, and immune modulation. Platelets can directly interact with pathogens, as well as with immune cells, by releasing cytokines and other signaling molecules. They also assist in tissue repair by promoting cell growth and the repair of endothelial damage. In the context of aging, platelets become hyper-reactive and prone to causing chronic low-grade inflammation, which is a hallmark of "inflammaging." This state of sustained, low-level inflammation contributes to the progression of age-related diseases such as cardiovascular disease, neurodegenerative disorders, and frailty [13].The interaction between these blood cells not only maintains immune surveillance but also plays a central role in regulating inflammation and tissue repair. For instance, monocytes and macrophages act as regulators of inflammation, and their altered function with aging contributes to the prolonged inflammatory state seen in older individuals. Similarly, age-related changes in neutrophil function lead to impaired pathogen clearance and increased susceptibility to infections. In this context, eosinophils and basophils also contribute to immunity, especially in allergic and parasitic conditions, though their activity can become dysregulated with aging, further compounding immune dysfunction [14].

Hematology and Aging: The Link between Blood and Longevity

Hematology, the study of blood and its disorders, plays a crucial role in understanding the biological mechanisms behind aging and longevity. As individuals age, their blood undergoes profound changes that not only affect the function of the circulatory system but also have wide-reaching implications for overall health. Blood cells, including red blood cells (RBCs), white blood cells (WBCs), and platelets, experience age-related alterations that influence not just immune function but also the body’s capacity to repair itself, fend off disease, and maintain homeostasis. These changes in blood composition and functionality can be linked to the overall decline in health associated with aging and may offer critical insights into how we can intervene to improve longevity and healthspan [15].

Red blood cells (RBCs) are perhaps the most well-known blood components, responsible for the essential task of oxygen transport throughout the body. As individuals age, the efficiency of RBCs gradually declines. This reduction in oxygen delivery affects many physiological processes, leading to symptoms such as fatigue, decreased physical endurance, and cognitive decline. The aging of RBCs is not merely a function of their reduced capacity to carry oxygen, but also the diminished ability of their membranes to resist oxidative damage, which impairs their longevity. Moreover, as RBCs age, their removal by the spleen and liver becomes less efficient, resulting in a buildup of dysfunctional cells in the circulation, further compounding the effects of reduced oxygenation [16].

White blood cells (WBCs), which are pivotal in defending the body against infections, also experience significant aging-related changes. The decline in the production and function of immune cells, particularly T-cells and B-cells, is a hallmark of immune aging, known as immunosenescence. The thymus, where T-cells mature, shrinks with age, reducing the production of naïve T-cells that are crucial for responding to new infections. Similarly, B-cells lose their ability to produce high-affinity antibodies, weakening the body's response to pathogens and vaccines. This gradual decline in immune function leads to increased susceptibility to infections, cancer, and autoimmune disorders, which significantly impacts longevity. Interestingly, the rise of chronic, low-grade inflammation—a condition referred to as "inflammaging"—is also driven by changes in WBCs, particularly in monocytes and macrophages. These cells, which regulate inflammation and tissue repair, become dysregulated with age, leading to a prolonged inflammatory state that accelerates the onset of age-related diseases [17-18].

Platelets, traditionally associated with coagulation, also play a critical role in immune responses and tissue repair. While platelets help seal wounds and prevent excessive bleeding, their function extends far beyond clotting. Inflammation is a central feature of aging, and platelets are key players in this process. As people age, platelets become more reactive, contributing to chronic inflammation, endothelial damage, and the progression of cardiovascular diseases. This overactive platelet response, compounded by changes in platelet adhesion and aggregation, contributes to the high incidence of vascular diseases in older adults, thus impacting both longevity and quality of life [19].The aging of hematopoietic stem cells (HSCs), which are responsible for generating all blood cell types, is a central factor in the decline of blood function. With age, the regenerative capacity of HSCs diminishes, leading to a reduced ability to produce new blood cells and repair damage. This depletion of HSC function not only affects blood cell turnover but also impairs immune function, as the replenishment of immune cells becomes less efficient. This decline in hematopoiesis is a key contributor to the weakened immune system seen in the elderly, leaving them more vulnerable to infections and other diseases [20].

The relationship between blood cells and aging suggests that by enhancing hematopoietic function, it may be possible to delay or even reverse certain aspects of aging. Research into stem cell therapies, gene editing, and cytokine treatments has shown promising results in rejuvenating blood cells and improving immune function in animal models. For instance, interventions designed to restore the function of hematopoietic stem cells could potentially lead to better immune responses, reduced inflammation, and improved tissue repair, ultimately promoting a longer and healthier life. Additionally, the manipulation of erythropoiesis (the process of RBC production) may improve oxygen delivery to tissues, thereby enhancing physical performance and cognitive function in older individuals [21].The link between blood, immunity, and aging suggests that strategies aimed at preserving or restoring blood cell function could hold the key to extending healthspan. By slowing the age-related decline in blood cell production and functionality, we may be able to delay the onset of age-related diseases such as cardiovascular disease, diabetes, and neurodegeneration. For example, anti-inflammatory therapies and immune-modulatory drugs could offer new approaches for mitigating the chronic inflammation that accelerates aging. Furthermore, blood transfusions or treatments that boost blood cell regeneration may become effective tools in combating frailty, muscle weakness, and cognitive decline in the elderly(Table 1)[22].

Table 1: Hematology and Aging: The Link between Blood and Longevity

Hematological Component	Age-Related Change	Longevity Implication	Key Mechanisms/Notes
Hematopoietic Stem Cells (HSCs)	Reduced self-renewal, myeloid bias	Impaired blood regeneration; increased susceptibility to infections and malignancy	DNA damage, epigenetic drift, mitochondrial dysfunction
Red Blood Cells (RBCs)	Decline in erythropoiesis; higher anemia prevalence	Reduced oxygen delivery, fatigue, frailty, organ vulnerability	Decreased EPO response, chronic inflammation, nutrient deficiencies
Platelets and Megakaryocytes	Altered platelet reactivity; increased thrombosis risk	Higher cardiovascular and cerebrovascular event rates	Pro-inflammatory state, increased platelet activation
Innate Immunity	Increased inflammatory monocytes, impaired neutrophil function	Promotes inflammaging, reduced pathogen clearance	NF-κB activation, oxidative stress, senescent immune cells
Adaptive Immunity	Decreased naïve T and B cells; thymic involution	Weakened immune surveillance; increased infection and cancer risk	Shrinking thymus, reduced lymphopoiesis, exhausted memory cells
Cytokine and Inflammatory Profile	Elevated IL-6, CRP, TNF-α	Accelerated atherosclerosis, neurodegeneration, frailty	Chronic immune activation, senescent cell secretome (SASP)
Clonal Hematopoiesis (CHIP)	Expansion of mutated clones (DNMT3A, TET2, ASXL1)	Higher cardiovascular risk, increased mortality, leukemia predisposition	Mutant clone-driven inflammation and altered macrophage biology
Coagulation System	Hypercoagulable shift with age	Greater thrombotic risk and reduced microvascular health	Elevated fibrinogen, endothelial dysfunction
Bone Marrow Microenvironment	Stromal aging, reduced niche support	Further HSC aging and impaired hematopoiesis	Altered MSC function, niche inflammation
Blood-Based Biomarkers	Changes in epigenetic age, proteomics, immune markers	Useful indicators of biological age and healthspan	DNA methylation clocks, inflammatory signatures, immune ratios

The Role of Inflammation in Aging and Longevity

Inflammation, often perceived as a protective response to injury or infection, takes on a more complex and potentially harmful role as we age. While acute inflammation is essential for healing and immune defense, chronic low-grade inflammation, known as inflammaging, emerges as a central feature of aging. This persistent, subclinical inflammation contributes significantly to the decline in physiological function, the development of age-related diseases, and the shortening of healthspan. Understanding the role of inflammation in aging is key to unlocking new therapeutic avenues aimed at promoting longevity and enhancing quality of life in older individuals [23-24].

Inflammaging refers to the gradual, chronic increase in pro-inflammatory markers in the body, even in the absence of obvious infection or injury. It is characterized by elevated levels of cytokines, such as interleukins (IL-6 and IL-1), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP). These molecules are normally

involved in the immune response but, over time, their persistent elevation can lead to tissue damage, altered immune function, and dysregulation of metabolic processes. The underlying causes of inflammaging are multifactorial, including cellular senescence, mitochondrial dysfunction, and the decline in immune system efficiency. Senescent cells, which accumulate with age, secrete inflammatory mediators that further perpetuate the cycle of chronic inflammation, making it a self-sustaining process. This chronic inflammatory state is linked to a wide array of age-related conditions, including cardiovascular disease, neurodegenerative diseases, arthritis, diabetes, and even cancer [25].

One of the most significant ways in which inflammation accelerates aging is by affecting the function of hematopoietic stem cells (HSCs), which are responsible for producing all blood cells, including those crucial for immune responses. Inflammaging negatively impacts HSC function, impairing the production of new immune cells and reducing the body's ability to fight infections and repair tissue. This decline in stem cell function is compounded by the systemic inflammation that disrupts the delicate balance between immune tolerance and immune activation. With age, the immune system becomes less capable of distinguishing between harmful invaders and the body's own tissues, increasing the risk of autoimmune diseases. Chronic inflammation also leads to endothelial dysfunction, where the inner lining of blood vessels becomes less effective in regulating blood flow, contributing to the development of cardiovascular disease [26].

Another area where inflammation intersects with aging is in the regulation of muscle function and bone health. Chronic low-grade inflammation contributes to the loss of lean muscle mass, a condition known as sarcopenia, which is common in older adults. Inflammatory cytokines, particularly TNF-α, play a central role in promoting muscle degradation, leading to frailty and reduced mobility. Similarly, inflammation accelerates osteoporosis by increasing bone resorption and decreasing bone formation. This results in fragile bones, making fractures more likely and hindering recovery. Therefore, the inflammatory processes that drive muscle and bone degeneration are pivotal in understanding why older adults experience a decline in physical strength, endurance, and overall mobility [27].

The connection between inflammation and aging has also been linked to cognitive decline and neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. Chronic systemic inflammation can promote neuroinflammation, which exacerbates neuronal damage and impairs cognitive function. Inflammatory cytokines in the brain, including IL-1 and TNF-α, have been shown to disrupt synaptic plasticity, hinder neural repair, and promote the accumulation of neurotoxic proteins such as amyloid-beta. This neuroinflammatory process is thought to contribute to the cognitive decline seen in aging and to the onset of Alzheimer's disease. Furthermore, the microglia, which are the resident immune cells of the central nervous system, become overactivated with age, leading to chronic inflammation in the brain and a vicious cycle of neurodegeneration [28-30].Inflammation's role in aging is not entirely negative, however. In the right context, it is necessary for tissue repair, immune surveillance, and combating infections. The challenge lies in the chronic, low-grade nature of inflammation associated with aging, which fails to resolve and instead drives the degenerative processes that underlie many age-related diseases. This chronic inflammation is a key driver of the aging phenotype, and its modulation presents a promising strategy for extending healthspan and potentially delaying the onset of age-related diseases(Table 2) [31].

Table 2: The Role of Inflammation in Aging and Longevity

Inflammatory Component	Age-Related Change	Impact on Longevity	Mechanisms / Pathophysiology
Chronic Low-Grade Inflammation (Inflammaging)	Persistent elevation of pro-inflammatory markers	Accelerates biological aging, increases morbidity	Senescent cell SASP, innate immune dysregulation
Cytokines (IL-6, TNF-α, CRP)	Elevated circulating levels	Promotes frailty, cardiovascular disease, cognitive decline	NF-κB activation, chronic immune stress
Innate Immune Activation	Increased inflammatory monocytes and macrophages	Heightened metabolic dysfunction, tissue degeneration	Mitochondrial damage, ROS production
Adaptive Immune Decline	Reduced naïve T/B cells, T-cell exhaustion	Reduced immune surveillance; increased infection and cancer risk	Thymic involution, restricted lymphocyte repertoire
Senescent Cells	Accumulation in tissues and blood	Shortened healthspan; impaired regeneration	SASP secretion (IL-1β, IL-6, MMPs)
Oxidative Stress and ROS	Increased ROS generation, impaired antioxidant defense	Damages DNA, proteins, lipids; promotes aging phenotypes	Mitochondrial dysfunction, chronic inflammation
Clonal Hematopoiesis–Driven Inflammation	Expansion of TET2/DNMT3A mutant clones	Higher cardiovascular mortality and systemic inflammation	Pro-inflammatory macrophage polarization
Metaflammation (Nutrient-Induced Inflammation)	Chronic overnutrition-induced immune activation	Increases metabolic aging, insulin resistance	NLRP3 inflammasome activation
Microbiome Dysbiosis	Loss of microbial diversity, increased gut permeability	Systemic inflammation and reduced longevity	Endotoxin leakage, immune activation
Coagulation–Inflammation Axis	Hypercoagulability linked to inflammation	Elevated risk of thrombosis and organ damage	Fibrinogen elevation, endothelial activation

Emerging Therapeutic Strategies: From Hematopoiesis to Immune Modulation

The complex relationship between hematopoiesis—the process by which blood cells are formed—and immune modulation has become a key area of research in the pursuit of innovative therapies for aging and age-related diseases. As the population ages, there is an increasing need for interventions that not only address the decline in blood cell production but also enhance immune function to combat the heightened susceptibility to infections, chronic inflammation, and various diseases. Emerging therapeutic strategies that target hematopoiesis and immune modulation offer exciting potential for rejuvenating the aging immune system, improving immune responses, and promoting overall health and longevity [32].

At the core of these therapeutic advancements is the ability to enhance hematopoiesis. Hematopoietic stem cells (HSCs) are the cornerstone of blood cell production. As individuals age, the regenerative capacity of HSCs diminishes, leading to a decline in the production of blood cells, particularly immune

cells, which in turn weakens the immune system. One promising strategy is stem cell-based therapies aimed at rejuvenating the HSC pool. Research has shown that it is possible to restore HSC function by manipulating the signaling pathways involved in HSC self-renewal and differentiation. For example, ex vivo expansion of HSCs and their transplantation into aged individuals could potentially rejuvenate the blood system and improve immune function. These approaches are still in early stages, but advances in gene editing technologies, such as CRISPR-Cas9, hold promise for more targeted and effective interventions [33-34].

In addition to enhancing hematopoiesis, immune modulation is becoming a key therapeutic strategy to improve immune responses in aging populations. As people age, their immune system becomes less adept at distinguishing between harmful invaders and the body's own tissues, resulting in an increased susceptibility to infections and autoimmune diseases. Immunotherapy techniques, such as the use of immune checkpoint inhibitors or the modulation of cytokine levels, have shown great potential in addressing the age-related decline in immune function. These therapies work by enhancing the activity of immune cells, such as T-cells and natural killer (NK) cells, which are crucial for detecting and eliminating pathogens and tumor cells. By reversing immune exhaustion or enhancing immune activation, these strategies aim to rejuvenate the immune system and restore its protective capacity [35-36].

Cytokine modulation also plays a pivotal role in emerging therapeutic strategies for immune regulation. Inflammation is a central feature of aging, and chronic low-grade inflammation, or inflammaging, is associated with the development of numerous age-related diseases, including cardiovascular disease, neurodegeneration, and cancer. By targeting specific inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP), researchers are developing therapies that aim to reduce chronic inflammation and improve tissue function. Monoclonal antibodies, small molecule inhibitors, and other cytokine-targeted therapies are being tested to suppress pro-inflammatory pathways, which could help alleviate the burden of chronic diseases in the elderly and promote a healthier aging process. These strategies also hold potential for treating autoimmune diseases, where the immune system mistakenly targets the body's own tissues [37].

Another promising therapeutic area is immune reprogramming, which involves resetting the immune system to a more youthful state. This approach targets immune cells that become dysfunctional with age, such as T-cells, B-cells, and macrophages. One such strategy involves the use of thymic rejuvenation, which aims to restore the thymus gland's ability to produce naive T-cells. The thymus naturally shrinks with age, leading to a decline in the number of new T-cells produced, which impairs immune surveillance. By using targeted therapies, including the administration of hormones or peptides, scientists are exploring ways to regenerate the thymus and restore T-cell output, thereby enhancing immune responses and improving overall immune system functionality. This type of therapeutic intervention could not only help prevent infections but also reduce the risk of age-related immune dysfunction, such as cancer and autoimmune disorders [38].

Gene editing technologies also hold promise in enhancing immune modulation and hematopoiesis. Advances in gene editing, particularly with the CRISPR-Cas9 system, have made it possible to target and correct genetic defects in HSCs or immune cells, offering potential treatments for blood disorders and immune deficiencies. By editing the genes responsible for immune cell function, researchers are exploring ways to enhance the body's ability to fight infections and cancer. In addition, gene editing could help address genetic causes of immunosenescence, potentially offering ways to rejuvenate aging immune cells and restore their functionality. These cutting-edge technologies could revolutionize the way we approach not only

immune deficiencies but also age-related declines in immune system function [39].

Furthermore, senolytics, a class of drugs that target and eliminate senescent cells—cells that have stopped dividing and contribute to chronic inflammation—are gaining attention as a potential therapeutic strategy. Senescent immune cells, which accumulate with age, secrete pro-inflammatory factors that promote aging-related diseases. By selectively targeting these senescent cells, senolytics can help reduce chronic inflammation and improve immune function, ultimately promoting healthier aging. Research into senolytics is still in the early stages, but these drugs show great promise in improving immune system function and extending healthspan [40]. Nutritional interventions and lifestyle modifications are emerging as complementary therapeutic strategies to support hematopoiesis and immune modulation. Studies have shown that dietary interventions, such as caloric restriction, the consumption of anti-inflammatory foods, and the modulation of the microbiome, can have a significant impact on immune function and aging. For example, polyphenols found in foods like berries, green tea, and olive oil have been shown to reduce inflammation and improve immune responses. Similarly, regular physical activity has been proven to enhance immune function, improve hematopoiesis, and reduce inflammation, contributing to a longer and healthier life [41-43].

Conclusion

The intersection of hematopoiesis and immune modulation is emerging as a critical frontier in the pursuit of healthier aging and enhanced longevity. As we age, the gradual decline in blood cell production, coupled with immune dysfunction and chronic inflammation, significantly impacts overall health, increasing susceptibility to a wide array of age-related diseases. However, recent advances in therapeutic strategies offer a promising path forward, targeting both the rejuvenation of hematopoietic stem cells and the regulation of immune responses. From stem cell therapies aimed at revitalizing hematopoiesis to cytokine modulation and immune reprogramming, innovative interventions are poised to restore immune system function and mitigate the effects of inflammaging. The potential to reverse or slow down the processes that contribute to immune aging opens up exciting new possibilities for addressing chronic conditions, such as cardiovascular disease, neurodegeneration, and cancer. Additionally, emerging strategies like senolytics and gene editing offer targeted ways to eliminate dysfunctional cells and enhance immune responses, further contributing to healthier aging.

References

1. Rodríguez-Rodero S, Fernández-Morera JL, Menéndez-Torre E, Calvanese V, Fernández AF, Fraga MF. Aging genetics and aging. Aging Dis. 2011;2(3):186-95.
2. Weyand CM, Goronzy JJ. Aging of the Immune System. Mechanisms and Therapeutic Targets. Ann Am Thorac Soc. 2016 Dec;13 Suppl 5(Suppl 5): S422-S428. doi: 10.1513/AnnalsATS.201602-095AW.
3. Hajishengallis G. Too old to fight? Aging and its toll on innate immunity. Mol Oral Microbiol. 2010 Feb;25(1):25-37. doi: 10.1111/j.2041-1014.2009.00562. x.
4. Kyriacou RP, Shibeeb S. Red Blood Cells and Human Aging: Exploring Their Biomarker Potential. Diagnostics (Basel). 2025;15(16):1993. doi: 10.3390/diagnostics15161993.
5. Rifkind JM, Nagababu E. Hemoglobin redox reactions and red blood cell aging. Antioxid Redox Signal. 2013;18(17):2274-83. doi: 10.1089/ars.2012.4867.
6. Groarke EM, Young NS. Aging and Hematopoiesis. Clin Geriatr Med. 2019;35(3):285-293. doi: 10.1016/j.cger.2019.03.001.
7. Ergen AV, Goodell MA. Mechanisms of hematopoietic stem cell aging. Exp Gerontol. 2010;45(4):286-90. doi: 10.1016/j.exger.2009.12.010.
8. Nicholson LB. The immune system. Essays Biochem. 2016;60(3):275-301. doi: 10.1042/EBC20160017.

9. Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010;125(2 Suppl 2): S3-23. doi: 10.1016/j.jaci.2009.12.980.
10. Risso A, Antonutto G. Red Blood Cells and Their Immunoregulatory Role. Med PrincPract. 2025:1-4. doi: 10.1159/000547047.
11. Tamang T, Baral S, Paing MP. Classification of White Blood Cells: A Comprehensive Study Using Transfer Learning Based on Convolutional Neural Networks. Diagnostics (Basel). 2022;12(12):2903. doi: 10.3390/diagnostics12122903.
12. Shaikh SB, Goracci C, Tjitropranoto A, Rahman I. Impact of aging on immune function in the pathogenesis of pulmonary diseases: potential for therapeutic targets. Expert Rev Respir Med. 2023;17(5):351-364. doi: 10.1080/17476348.2023.2205127.
13. Sonmez O, Sonmez M. Role of platelets in immune system and inflammation. Porto Biomed J. 2017;2(6):311-314. doi: 10.1016/j.pbj.2017.05.005.
14. Parihar A, Eubank TD, Doseff AI. Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death. J Innate Immun. 2010;2(3):204-15. doi: 10.1159/000296507.
15. Fujino T, Asada S, Goyama S, Kitamura T. Mechanisms involved in hematopoietic stem cell aging. Cell Mol Life Sci. 2022;79(9):473. doi: 10.1007/s00018-022-04356-5.
16. Daraghmeh DN, Karaman R. The Redox Process in Red Blood Cells: Balancing Oxidants and Antioxidants. Antioxidants (Basel). 2024;14(1):36. doi: 10.3390/antiox14010036.
17. Yu W, Yu Y, Sun S, Lu C, Zhai J, Lei Y, Bai F, Wang R, Chen J. Immune Alterations with Aging: Mechanisms and Intervention Strategies. Nutrients. 2024;16(22):3830. doi: 10.3390/nu16223830.
18. Farheen S, Agrawal S, Zubair S, Agrawal A, Jamal F, Altaf I, Kashif Anwar A, Umair SM, Owais M. Patho-Physiology of Aging and Immune-Senescence: Possible Correlates with Comorbidity and Mortality in Middle-Aged and Old COVID-19 Patients. Front Aging. 2021; 2:748591. doi: 10.3389/fragi.2021.748591.
19. Scridon A. Platelets and Their Role in Hemostasis and Thrombosis-From Physiology to Pathophysiology and Therapeutic Implications. Int J Mol Sci. 2022;23(21):12772. doi: 10.3390/ijms232112772.
20. Mejia-Ramirez E, Florian MC. Understanding intrinsic hematopoietic stem cell aging. Haematologica. 2020;105(1):22-37. doi: 10.3324/haematol.2018.211342.
21. Cui J, Li X, Liu B, Dong C, Chang Y. Hematopoietic Stem Cell Aging: Mechanisms, Microenvironment Influences, and Rejuvenation Strategies. Bioengineering (Basel). 2025;12(11):1166. doi: 10.3390/bioengineering12111166.
22. Weyand CM, Goronzy JJ. Aging of the Immune System. Mechanisms and Therapeutic Targets. Ann Am Thorac Soc. 2016;13 Suppl 5(Suppl 5): S422-S428. doi: 10.1513/AnnalsATS.201602-095AW. PMID: 28005419; PMCID: PMC5291468.
23. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15(9):505-522. doi: 10.1038/s41569-018-0064-2.
24. Teissier T, Boulanger E, Cox LS. Interconnections between Inflammageing and Immunosenescence during Ageing. Cells. 2022;11(3):359. doi: 10.3390/cells11030359.
25. Batista MA, Calvo-Fortes F, Silveira-Nunes G, Camatta GC, Speziali E, Turroni S, Teixeira-Carvalho A, Martins-Filho OA, Neretti N, Maioli TU, Santos RR, Brigidi P, Franceschi C, Faria AMC. Inflammaging in Endemic Areas for Infectious Diseases. Front Immunol. 2020; 11:579972. doi: 10.3389/fimmu.2020.579972.
26. Chen Z, Ju Z. Inflamm-aging of hematopoietic stem cells. Blood Sci. 2019;1(2):141-143. doi: 10.1097/BS9.0000000000000029.
27. Dalle S, Rossmeislova L, Koppo K. The Role of Inflammation in Age-Related Sarcopenia. Front Physiol. 2017; 8:1045. doi: 10.3389/fphys.2017.01045.

28. Bayraktaroglu I, Ortí-Casañ N, Van Dam D, De Deyn PP, Eisel ULM. Systemic inflammation as a central player in the initiation and development of Alzheimer's disease. Immun Ageing. 2025;22(1):33. doi: 10.1186/s12979-025-00529-5.
29. Soraci L, Corsonello A, Paparazzo E, Montesanto A, Piacenza F, Olivieri F, Gambuzza ME, Savedra EV, Marino S, Lattanzio F, Biscetti L. Neuroinflammaging: A Tight Line Between Normal Aging and Age-Related Neurodegenerative Disorders. Aging Dis. 2024;15(4):1726-1747. doi: 10.14336/AD.2023.1001.
30. Soraci L, Corsonello A, Paparazzo E, Montesanto A, Piacenza F, Olivieri F, Gambuzza ME, Savedra EV, Marino S, Lattanzio F, Biscetti L. Neuroinflammaging: A Tight Line Between Normal Aging and Age-Related Neurodegenerative Disorders. Aging Dis. 2024;15(4):1726-1747. doi: 10.14336/AD.2023.1001.
31. Saavedra D, Añé-Kourí AL, Barzilai N, Caruso C, Cho KH, Fontana L, Franceschi C, Frasca D, Ledón N, Niedernhofer LJ, Pereira K, Robbins PD, Silva A, Suarez GM, Berghe WV, von Zglinicki T, Pawelec G, Lage A. Aging and chronic inflammation: highlights from a multidisciplinary workshop. Immun Ageing. 2023;20(1):25. doi: 10.1186/s12979-023-00352-w.
32. Groarke EM, Young NS. Aging and Hematopoiesis. Clin Geriatr Med. 2019;35(3):285-293. doi: 10.1016/j.cger.2019.03.001.
33. Cui J, Li X, Liu B, Dong C, Chang Y. Hematopoietic Stem Cell Aging: Mechanisms, Microenvironment Influences, and Rejuvenation Strategies. Bioengineering (Basel). 2025;12(11):1166. doi: 10.3390/bioengineering12111166.
34. Raghav PK, Gangenahalli G, Hara T. Editorial: Advancements in hematopoietic stem cell proliferation and self-renewal maintenance. Front Cell Dev Biol. 2025 13:1607145. doi: 10.3389/fcell.2025.1607145.
35. Cisneros B, García-Aguirre I, Unzueta J, Arrieta-Cruz I, González-Morales O, Domínguez-Larrieta JM, Tamez-González A, Leyva-Gómez G, Magaña JJ. Immune system modulation in aging: Molecular mechanisms and therapeutic targets. Front Immunol. 2022; 13:1059173. doi: 10.3389/fimmu.2022.1059173.
36. Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. J Clin Invest. 2013;123(3):958-65. doi: 10.1172/JCI64096.
37. Rea IM, Gibson DS, McGilligan V, McNerlan SE, Alexander HD, Ross OA. Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines. Front Immunol. 2018; 9:586. doi: 10.3389/fimmu.2018.00586.
38. Gaspal F, Narendran P, Ng STH, Price MJ, Wraith DC. 'Immune reset plus': the case for combining immunotherapies to maintain self-tolerance in autoimmune diseases. Front Immunol. 2025; 16:1634090. doi: 10.3389/fimmu.2025.1634090.
39. Kolanu ND. CRISPR-Cas9 Gene Editing: Curing Genetic Diseases by Inherited Epigenetic Modifications. Glob Med Genet. 2024 Mar 29;11(1):113-122. doi: 10.1055/s-0044-1785234.
40. Robbins PD, Jurk D, Khosla S, Kirkland JL, LeBrasseur NK, Miller JD, Passos JF, Pignolo RJ, Tchkonia T, Niedernhofer LJ. Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span. Annu Rev PharmacolToxicol. 2021; 61:779-803. doi: 10.1146/annurev-pharmtox-050120-105018.
41. Vijay A, Simpson L, Tooley M, Turley S, Kouraki A, Kelly A, Menni C, Armstrong J, Jones S, Valdes AM. The anti-inflammatory effects of three different dietary supplement interventions. J Transl Med. 2025 Oct 16;23(1):1081. doi: 10.1186/s12967-025-07167-x.
42. Yu X, Pu H, Voss M. Overview of anti-inflammatory diets and their promising effects on non-communicable diseases. Br J Nutr. 2024;132(7):898-918. doi: 10.1017/S0007114524001405.

Abbreviations

CHIP – Clonal Hematopoiesis of Indeterminate Potential
CRP – C-Reactive Protein
DNA – Deoxyribonucleic Acid
EPO – Erythropoietin
HSC – Hematopoietic Stem Cell
IL-1β – Interleukin-1 Beta
IL-6 – Interleukin-6
MSC – Mesenchymal Stromal Cell
NF-κB– Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells
RBC – Red Blood Cell
ROS – Reactive Oxygen Species
SASP – Senescence-Associated Secretory Phenotype
TNF-α – Tumor Necrosis Factor Alpha

Access this Article in Online	
Quick Response Code	Website: www.ijcrcps.com Subject: Haematology
DOI: 10.22192/ijcrcps.2026.13.03.003	

How to cite this article:
Emmanuel Ifeanyi Obeagu. (2026). Blood, Immunity and Longevity: The Untapped Potential of Hematological Research: A Narrative Review. Int. J. Curr. Res. Chem. Pharm. Sci. 13(3): 20-32.
DOI: http://dx.doi.org/10.22192/ijcrcps.2026.13.03.003

